Papers on empagliflozin
512 papers124 new in 30 days
Thursday, November 19
The Journal of Clinical and Aesthetic Dermatology
Suspected Pityriasis Rubra Pilaris-Like Eruption Following SGLT2 Inhibitor Therapy: A Case Report
Case reportSGLT2 inhibitors
Respiratory Medicine
Prospective Real-World Evaluation of Empagliflozin on Pulmonary Function and Exercise Capacity in Patients with Type 2 Diabetes and COPD
Non-randomized trial in 31 peopleEmpagliflozin
Wednesday, November 18
Canadian Journal of Kidney Health and Disease
Systematic Review of the Cost-Utility of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Chronic Kidney Disease Management

Systematic reviewSGLT2 inhibitors
Medical Sciences
Cardiovascular Effects of a Broad Range of Interventions for Adults with Prediabetes: A Systematic Review of Randomized Controlled Trials

Systematic review of randomized trialsLifestyle interventions
Monday, November 16
Diabetes, Obesity & Metabolism
Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 10 mg in Korean Adults With Type 2 Diabetes: A Multicentre, Randomised, Double‐Blind, Placebo‐Controlled Phase III Trial
Randomized trial in 195 peopleType 2 diabetes
Sunday, November 15
Biochemical and Biophysical Research Communications
Biochemical reassessment of the activation of PANK1 by SGLT2 inhibitors

Experiments in human cellsMechanisms
Saturday, November 14
Journal of Diabetes Investigation
Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial

Randomized trial in 119 peopleType 2 diabetes
Review of Clinical Pharmacology and Pharmacokinetics - International Edition
Empagliflozin-associated emphysematous cystitis: a systematic review of published case reports
Systematic reviewEmpagliflozin
Hormone and Metabolic Research
Association of Sodium-Glucose Cotransporter-2 Inhibitor Use with Laboratory- and Anthropometry-Derived Indices of Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Retrospective Cohort Study
Cohort study of 493 peopleSGLT2 inhibitors
Friday, November 13
bioRxiv
Biochemical reassessment of the activation of PANK1 by SGLT2 inhibitors
Preprint: experiments in human cellsMechanisms
American Heart Journal Plus
SGLT2 inhibitors for peripartum cardiomyopathy: A call for a dedicated trial

CommentaryInterventions
Thursday, November 12
Frontiers in Endocrinology
Exercise and Empagliflozin Each Attenuate Cardiac Injury in Diabetic Cardiomyopathy via Suppression of Inflammation and Modulation of Ferroptosis, without Synergistic Benefit
Accepted, not yet published: experiments in miceEmpagliflozin
Wednesday, November 11
Tuesday, November 10
BMC Cardiovascular Disorders
Adoption and diffusion of SGLT2 inhibitors among cardiologists in medicare part D, 2019-2023: a provider-level observational study

Cross-sectional study of 24,000 peoplePopulations
Diabetes, Obesity & Metabolism
Two‐Year Trajectories of DIAL2 ‐Predicted Cardiovascular Risk After Initiation of Semaglutide, Empagliflozin or Their Combination: The DIAL ‐ STEP Study
Cohort study of 332 peopleCardiovascular disease
European Journal of Pharmacology
Restoring Myocardial Sodium–Calcium Homeostasis: A Central Mechanism of Empagliflozin in Heart Failure

ReviewEmpagliflozin
Monday, November 9
AHA Scientific Sessions 2026 Abstract
SGLT2 Inhibition in Pericarditis: Pericardial and Mortality Outcomes in Type 2 Diabetes
Cohort study of 5,782 peopleSGLT2 inhibitors
AHA Scientific Sessions 2026 Abstract
Sodium-Glucose Cotransporter 2 Inhibitors and Mortality in Precapillary Pulmonary Hypertension
Cohort study of 28,506 peopleSGLT2 inhibitors
AHA Scientific Sessions 2026 Abstract
Safety of Early SGLT2i Initiation in Acute Heart Failure Admissions in Patients with Elevated Hemoglobin A1c: A Propensity-Matched Real-World Study
Cohort study of 11,583 peopleSGLT2 inhibitors
AHA Scientific Sessions 2026 Abstract
Cardiac Magnetic Resonance-Based Tissue Characterization in Nonhuman Primate Disease Models of Heart Failure - Translational Relevance and Pharmacodynamic Response
Experiments in monkeysInterventions
AHA Scientific Sessions 2026 Abstract
Sodium-Glucose Cotransporter-2 Inhibitors Increase Estimated Glomerular Filtration Rate Slope and Ameliorate Clinical Outcomes After Catheter Ablation in Atrial Fibrillation Patients with Heart Failure
Randomized trial in 200 peopleSGLT2 inhibitors
AHA Scientific Sessions 2026 Abstract
SGLT2 Inhibitors and Postoperative Atrial Fibrillation in Type 2 Diabetes Following Coronary Artery Bypass Grafting: A Target Trial Emulation
Cohort study of 3,276 peopleSGLT2 inhibitors
AHA Scientific Sessions 2026 Abstract
Effects of Sotagliflozin and Empagliflozin on Thrombus Formation in Healthy Volunteers: A Randomized Crossover Trial
Randomized trial in 15 peopleSotagliflozin
AHA Scientific Sessions 2026 Abstract
An X-Learner Causal Forest Meta-Analysis for Personalized SGLT2i/GLP-1 Selection in HFpEF
Computational studySGLT2 inhibitors
AHA Scientific Sessions 2026 Abstract
Load-Dependent Effects of Sodium Glucose Co-Transporter Inhibitors on Work in Human Hypertrophic Cardiomyopathy Living Myocardial Slices
Experiments in human cellsMechanisms
AHA Scientific Sessions 2026 Abstract
Differential Effects of Ovarian Hormone Deprivation and Empagliflozin on Cardiac Remodeling in Type 2 Diabetic Mice
Experiments in 35 miceEmpagliflozin
Sunday, November 8
Journal of Cardiothoracic and Vascular Anesthesia
Effects of the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin on Perioperative Endothelial Function in Patients Undergoing Cardiac Surgery: An Exploratory Analysis of MERCURI-1
Randomized trial in peopleSGLT2 inhibitors


